4D Molecular Therapeutics (NASDAQ:FDMT) Posts Earnings Results, Misses Estimates By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) released its earnings results on Friday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock opened at $4.53 on Friday. The stock’s fifty day simple moving average is $5.22 and its 200 day simple moving average is $8.59. The firm has a market cap of $209.41 million, a price-to-earnings ratio of -1.59 and a beta of 2.81. 4D Molecular Therapeutics has a one year low of $4.20 and a one year high of $36.25.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on FDMT shares. Royal Bank of Canada lowered their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. Leerink Partners lowered their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. Bank of America lowered their target price on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Morgan Stanley decreased their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. Finally, BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $40.00 to $15.00 in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.